Chaudry M. Mushtaq, MD

Articles by Chaudry M. Mushtaq, MD

Irinotecan in the Management of Patients With Pancreatic Cancer

ByMark R. Green, MD,Melinda Harper, RN,Ahmad R. Safa, MD, PhD,Carol A. Sherman, MD,Chaudry M. Mushtaq, MD,Hamid Bahadori, MD,Frank J. Brescia, MD,Caio Max S. Rocha Lima, MD

December 3rd 2000

Synergy with no overlapping toxicities has been demonstrated for the combination of irinotecan ( Camptosar, CPT-11) and gemcitabine (Gemzar) in vitro. Results of a single-institution phase I study in which patients with

Latest Updated Articles

Irinotecan in the Management of Patients With Pancreatic Cancer
Published: December 3rd 2000 | Updated:

Chaudry M. Mushtaq, MD

Articles by Chaudry M. Mushtaq, MD

Irinotecan in the Management of Patients With Pancreatic Cancer

Latest Updated Articles

Trending on CancerNetwork

More Global Expertise and Talent Are Needed to Administer Cell Therapies

FDA Grants Priority Review to Enfortumab Vedotin Combo in MIBC Subset

Adaptive Treatment and Other Advances May Drive Radiotherapy Field Forward

Region-Based Genetic Disorders Affect Cancer Treatment Decisions

Simultaneous Integrated Boost Radiotherapy Improves PFS in Cervical Cancer